Mark N. Alshak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark N. Alshak has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Jim Hu
Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY
4 shared publications Neal Patel
Department of Urology, Weill Cornell Medicine, New York, NY
4 shared publicationsArt Sedrakyan
Department of Health Services and Policy Research, Weill Cornell Medicine, New York, NY
3 shared publicationsAssem Jabri
Division of General Internal Medicine, Weill Cornell Medicine, New York, NY, United States
3 shared publicationsMonika M. Safford
Division of General Internal Medicine, Weill Cornell Medicine, New York, NY, United States
3 shared publicationsAaron A. Laviana
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN
2 shared publications
Latest Publications
- 26 July 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 32 (11) , 1020-1026.e1
Trends and Outcomes of Ureteral and Bladder Injury Intraoperatively Repaired During Open and Minimally Invasive Hysterectomy From 2013 to 2023: A National Matched Cohort Study
- 26 July 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 32 (11) , 1020-1026.e1
Trends and Outcomes of Ureteral and Bladder Injury Intraoperatively Repaired During Open and Minimally Invasive Hysterectomy From 2013 to 2023: A National Matched Cohort Study
- 14 May 2025
- Published by Wiley in BJU International
- Vol. 136 (3) , 464-472
Prostate cancer active surveillance in solid organ transplant: a matched study and literature review
Objectives: To evaluate outcomes of prostate cancer (PCa) active surveillance (AS) in patients with versus without solid organ transplant (SOT), as the safety of PCa AS in patients with SOT remains understudied. We also performed a literature review to identify all studies describing PCa AS in patients with SOT. Patients and Methods: A retrospective study was conducted for patients with SOT (kidney, liver, heart, lung) with a diagnosis of PCa enrolled into AS either before or after SOT. Using prospectively collected information, they were matched with non‐SOT AS patients at PCa diagnosis by age, race, prostate‐specific antigen, and Gleason Grade Group (GGG). A scoping review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. Results: A total of 32 SOT AS patients were matched with 99 non‐SOT AS patients. After matching, there was no significant difference in baseline demographics. 34% were enrolled into AS before SOT. The median time on AS for patients with and without SOT was 4.7 and 4.98 years, respectively ( P = 0.87). In all, 53% of patients with SOT and 54.5% those without SOT were still on AS ( P = 0.99). In all, 28.1% of patients with and 39.4% without SOT progressed to definitive treatment ( P = 0.30), and there were no differences in rates of grade re‐classification or GGG at definitive treatment. No systemic disease progression or PCa‐specific deaths occurred. In the literature, we identified and reviewed 11 studies and found 99 patients enrolled into AS either before ( n = 33) or after ( n = 66) SOT. We did not identify a safety signal. Conclusion: We present the largest series of patients with PCa on AS with SOT. In patients with SOT and PCa on AS, a surveillance strategy appears safe and has similar outcomes as those without SOT on AS. Our review found a paucity of AS data in the SOT setting suggesting that further research is warranted.
- 14 May 2025
- Published by Wiley in BJU International
- Vol. 136 (3) , 464-472
Prostate cancer active surveillance in solid organ transplant: a matched study and literature review
Objectives: To evaluate outcomes of prostate cancer (PCa) active surveillance (AS) in patients with versus without solid organ transplant (SOT), as the safety of PCa AS in patients with SOT remains understudied. We also performed a literature review to identify all studies describing PCa AS in patients with SOT. Patients and Methods: A retrospective study was conducted for patients with SOT (kidney, liver, heart, lung) with a diagnosis of PCa enrolled into AS either before or after SOT. Using prospectively collected information, they were matched with non‐SOT AS patients at PCa diagnosis by age, race, prostate‐specific antigen, and Gleason Grade Group (GGG). A scoping review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. Results: A total of 32 SOT AS patients were matched with 99 non‐SOT AS patients. After matching, there was no significant difference in baseline demographics. 34% were enrolled into AS before SOT. The median time on AS for patients with and without SOT was 4.7 and 4.98 years, respectively ( P = 0.87). In all, 53% of patients with SOT and 54.5% those without SOT were still on AS ( P = 0.99). In all, 28.1% of patients with and 39.4% without SOT progressed to definitive treatment ( P = 0.30), and there were no differences in rates of grade re‐classification or GGG at definitive treatment. No systemic disease progression or PCa‐specific deaths occurred. In the literature, we identified and reviewed 11 studies and found 99 patients enrolled into AS either before ( n = 33) or after ( n = 66) SOT. We did not identify a safety signal. Conclusion: We present the largest series of patients with PCa on AS with SOT. In patients with SOT and PCa on AS, a surveillance strategy appears safe and has similar outcomes as those without SOT on AS. Our review found a paucity of AS data in the SOT setting suggesting that further research is warranted.
- 21 October 2021
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 157, 104622
Comparing automated vs. manual data collection for COVID-specific medications from electronic health records
- 21 October 2021
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 157, 104622
Comparing automated vs. manual data collection for COVID-specific medications from electronic health records
- Open Access
- 17 November 2020
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (10) , 855-858
Obesity and COVID-19 in New York City: A Retrospective Cohort Study
- 17 November 2020
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (10) , 855-858
Open AccessObesity and COVID-19 in New York City: A Retrospective Cohort Study
- Top Cited Papers
- 11 June 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (24) , 2372-2374
Clinical Characteristics of Covid-19 in New York City
The world is in the midst of the coronavirus disease 2019 (Covid-19) pandemic,1,2 and New York City has emerged as an epicenter. Here, we characterize the first 393 consecutive patients with Covid-19 who were admitted to two hospitals in New York City.
- 11 June 2020
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (24) , 2372-2374
Top Cited PapersClinical Characteristics of Covid-19 in New York City
The world is in the midst of the coronavirus disease 2019 (Covid-19) pandemic,1,2 and New York City has emerged as an epicenter. Here, we characterize the first 393 consecutive patients with Covid-19 who were admitted to two hospitals in New York City.
- Open Access
- 9 December 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0226285
Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series
To validate prognostic factors and determine the impact of obesity, hypertension, smoking and diabetes mellitus (DM) on risk of recurrence after surgery in patients with localized renal cell carcinoma (RCC). We performed a retrospective cohort study among patients that underwent partial or radical nephrectomy at Weill Cornell Medicine for RCC and collected preoperative information on RCC risk factors, as well as pathological data. Cases were reviewed for radiographic evidence of RCC recurrence. A Cox proportional-hazards model was developed to determine the contribution of RCC risk factors to recurrence risk. Disease-free survival and overall survival were analyzed using the Kaplan-Meier method and log-rank test. We identified 873 patients who underwent surgery for RCC between the years 2000–2015. In total 115 patients (13.2%) experienced a disease recurrence after a median follow up of 4.9 years. In multivariate analysis, increasing pathological T-stage (HR 1.429, 95% CI 1.265–1.614) and Nuclear grade (HR 2.376, 95% CI 1.734–3.255) were independently associated with RCC recurrence. In patients with T1-2 tumors, DM was identified as an additional independent risk factor for RCC recurrence (HR 2.744, 95% CI 1.343–5.605). Patients with DM had a significantly shorter median disease-free survival (1.5 years versus 2.6 years, p = 0.004), as well as median overall survival (4.1 years, versus 5.8 years, p<0.001). We validated high pathological T-stage and nuclear grade as independent risk factors for RCC recurrence following nephrectomy. DM is associated with an increased risk of recurrence among patients with early stage disease.
- 9 December 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0226285
Open AccessValidation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series
To validate prognostic factors and determine the impact of obesity, hypertension, smoking and diabetes mellitus (DM) on risk of recurrence after surgery in patients with localized renal cell carcinoma (RCC). We performed a retrospective cohort study among patients that underwent partial or radical nephrectomy at Weill Cornell Medicine for RCC and collected preoperative information on RCC risk factors, as well as pathological data. Cases were reviewed for radiographic evidence of RCC recurrence. A Cox proportional-hazards model was developed to determine the contribution of RCC risk factors to recurrence risk. Disease-free survival and overall survival were analyzed using the Kaplan-Meier method and log-rank test. We identified 873 patients who underwent surgery for RCC between the years 2000–2015. In total 115 patients (13.2%) experienced a disease recurrence after a median follow up of 4.9 years. In multivariate analysis, increasing pathological T-stage (HR 1.429, 95% CI 1.265–1.614) and Nuclear grade (HR 2.376, 95% CI 1.734–3.255) were independently associated with RCC recurrence. In patients with T1-2 tumors, DM was identified as an additional independent risk factor for RCC recurrence (HR 2.744, 95% CI 1.343–5.605). Patients with DM had a significantly shorter median disease-free survival (1.5 years versus 2.6 years, p = 0.004), as well as median overall survival (4.1 years, versus 5.8 years, p<0.001). We validated high pathological T-stage and nuclear grade as independent risk factors for RCC recurrence following nephrectomy. DM is associated with an increased risk of recurrence among patients with early stage disease.
- Open Access
- 4 November 2019
- Published by Springer Nature in Cureus
- Vol. 11 (11) , e6072
Mechanical Thrombectomy for Submassive Pulmonary Embolism in an Adult with Duodenal Adenocarcinoma and Brain Metastases
A 52-year-old African American man with small bowel adenocarcinoma metastatic to the brain and leptomeninges was found to have an acute pulmonary embolism while hospitalized for acute lower limb weakness, bowel, and urinary incontinence. He had an elevated troponin, echocardiographic findings concerning for right heart failure, and bilateral segmental and subsegmental pulmonary artery perfusion deficits with right pulmonary artery thrombus on CT angiography. Given the laboratory and radiographic findings with normotensive blood pressure, the patient was diagnosed with a submassive pulmonary embolism. After deliberation with interventional radiology and hematology, the patient underwent mechanical thrombectomy and was treated with therapeutic anticoagulation. Mechanical thrombectomy revealed substantial clot burden in the central pulmonary arteries and yielded a significant improvement in hypoxia and dyspnea. This case was an excellent exercise in therapeutic decision-making amidst a dynamic disease process that required integration of numerous clinical and diagnostic data points, including empiric anticoagulation with high clinical suspicion of acute pulmonary embolism, review of contraindications to anticoagulation and thrombolysis in metastatic malignancy, and the decision to pursue mechanical thrombectomy in the setting of contraindications to catheter-directed thrombolysis.
- 4 November 2019
- Published by Springer Nature in Cureus
- Vol. 11 (11) , e6072
Open AccessMechanical Thrombectomy for Submassive Pulmonary Embolism in an Adult with Duodenal Adenocarcinoma and Brain Metastases
A 52-year-old African American man with small bowel adenocarcinoma metastatic to the brain and leptomeninges was found to have an acute pulmonary embolism while hospitalized for acute lower limb weakness, bowel, and urinary incontinence. He had an elevated troponin, echocardiographic findings concerning for right heart failure, and bilateral segmental and subsegmental pulmonary artery perfusion deficits with right pulmonary artery thrombus on CT angiography. Given the laboratory and radiographic findings with normotensive blood pressure, the patient was diagnosed with a submassive pulmonary embolism. After deliberation with interventional radiology and hematology, the patient underwent mechanical thrombectomy and was treated with therapeutic anticoagulation. Mechanical thrombectomy revealed substantial clot burden in the central pulmonary arteries and yielded a significant improvement in hypoxia and dyspnea. This case was an excellent exercise in therapeutic decision-making amidst a dynamic disease process that required integration of numerous clinical and diagnostic data points, including empiric anticoagulation with high clinical suspicion of acute pulmonary embolism, review of contraindications to anticoagulation and thrombolysis in metastatic malignancy, and the decision to pursue mechanical thrombectomy in the setting of contraindications to catheter-directed thrombolysis.